SHIRE PLC (NASDAQ:SHPG) Files An 8-K Other EventsItem 8.01. Other Eventsp
Shire plc has issued the press releases attached hereto as Exhibits 99.1, 99.2, 99.3 and 99.4 which are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits. The following exhibits are filed herewith: |
| 99.1 | Press Release dated April 3, 2018 |
| 99.2 | Press Release dated April 3, 2018 |
| 99.3 | Press Release dated April 3, 2018 |
| 99.4 | Press Release dated April 3, 2018 |
EXHIBIT INDEX
|
ExhibitNo. |
Description |
| 99.1 | Press Release dated April 3, 2018 |
| 99.2 | Press Release dated April 3, 2018 |
| 99.3 | Press Release dated April 3, 2018 |
| 99.4 | Press Release dated April 3, 2018 |
Shire plc ExhibitEX-99.1 2 dp89023_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release www.shire.com Director Declaration April 3,…To view the full exhibit click here
About SHIRE PLC (NASDAQ:SHPG)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
